Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn's Akynzeo for CINV prevention receives EC approval

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

Researchers find that exercise may slow tumor growth, improve chemotherapy

Researchers find that exercise may slow tumor growth, improve chemotherapy

Transplantation conditioning choices impact on CML outcomes revealed

Transplantation conditioning choices impact on CML outcomes revealed

Promising results for stem cell therapy in MS

Promising results for stem cell therapy in MS

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

APHON announces recipients of 2014 APHON Membership Awards

APHON announces recipients of 2014 APHON Membership Awards

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Sclerosis patients treated with HSCT experience better long-term event-free survival

Sclerosis patients treated with HSCT experience better long-term event-free survival

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014